147 related articles for article (PubMed ID: 2834736)
21. Persistence and class-specificity of neutralizing antibody response induced by trypsin-cleaved type 3 poliovirus in mice.
Roivainen M; Piirainen L; Hovi T
Vaccine; 1993; 11(7):713-7. PubMed ID: 7688171
[TBL] [Abstract][Full Text] [Related]
22. Virus-like particle vaccines for poliovirus types 1, 2, and 3 with enhanced thermostability expressed in insect cells.
Xu Y; Ma S; Huang Y; Chen F; Chen L; Ding D; Zheng Y; Li H; Xiao J; Feng J; Peng T
Vaccine; 2019 Apr; 37(17):2340-2347. PubMed ID: 30922699
[TBL] [Abstract][Full Text] [Related]
23. New poliovirus vaccines: a molecular approach.
Almond JW; Stanway G; Cann AJ; Westrop GD; Evans DM; Ferguson M; Minor PD; Spitz M; Schild GC
Vaccine; 1984 Sep; 2(3):177-84. PubMed ID: 6085198
[TBL] [Abstract][Full Text] [Related]
24. Reactivity of neutralizing antibodies with different specificities to H particles of poliovirus.
Urasawa T; Urasawa S; Taniguchi K
Microbiol Immunol; 1979; 23(7):651-7. PubMed ID: 228166
[TBL] [Abstract][Full Text] [Related]
25. Mapping of the epitopes of poliovirus type 2 in complex with antibodies.
Bannwarth L; Girerd-Chambaz Y; Arteni A; Guigner JM; Ronzon F; Manin C; Vénien-Bryan C
Mol Immunol; 2015 Oct; 67(2 Pt B):233-9. PubMed ID: 26059753
[TBL] [Abstract][Full Text] [Related]
26. Antigenicity and immunogenicity of poliovirus capsid proteins.
van Wezel AL; van der Marel P; Hazendonk TG; Boer-Bak V; Henneke MA
Dev Biol Stand; 1983; 55():209-15. PubMed ID: 6203795
[TBL] [Abstract][Full Text] [Related]
27. Modulation of humoral response to a 12-amino-acid site on the poliovirus virion.
Icenogle JP; Minor PD; Ferguson M; Hogle JM
J Virol; 1986 Oct; 60(1):297-301. PubMed ID: 3018295
[TBL] [Abstract][Full Text] [Related]
28. Mapping of type 1 poliovirus neutralization epitopes.
Blondel B; Crainic R; Dufraisse G; Candréa A; Horaud F
Dev Biol Stand; 1985; 60():337-42. PubMed ID: 2412917
[TBL] [Abstract][Full Text] [Related]
29. [Mouse neurovirulence of antigenic chimeras (type I/II) of polioviruses].
Dai C
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Feb; 15(1):34-8. PubMed ID: 7686824
[TBL] [Abstract][Full Text] [Related]
30. Induction of virus-neutralizing antibodies by bacteria expressing the C3 poliovirus epitope in the periplasm. The route of immunization influences the isotypic distribution and the biologic activity of the antipoliovirus antibodies.
LeClerc C; Martineau P; Van der Werf S; Deriaud E; Duplay P; Hofnung M
J Immunol; 1990 Apr; 144(8):3174-82. PubMed ID: 2157762
[TBL] [Abstract][Full Text] [Related]
31. A national cross-sectional study for poliovirus seroprevalence in the Republic of Korea in 2012: implication for deficiency in immunity to polio among middle-aged people.
Kim HJ; Hwang S; Lee S; Kwon Y; Park K; Park YJ; Bae GR; Lee SW; Jeong YS; Hyeon JY
BMC Infect Dis; 2015 Mar; 15():164. PubMed ID: 25881203
[TBL] [Abstract][Full Text] [Related]
32. Induction of neutralizing antibodies by all three structural poliovirus polypeptides.
Dernick R; Heukeshoven J; Hilbrig M
Virology; 1983 Oct; 130(1):243-6. PubMed ID: 6314647
[TBL] [Abstract][Full Text] [Related]
33. Induction of neutralizing antibodies by type 1 poliovirus VP1 capsid polypeptide.
Crainic R; Blondel B; Horaud F
Dev Biol Stand; 1983; 55():185-9. PubMed ID: 6329856
[TBL] [Abstract][Full Text] [Related]
34. Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus.
Minor PD; Ferguson M; Phillips A; Magrath DI; Huovilainen A; Hovi T
J Gen Virol; 1987 Jul; 68 ( Pt 7)():1857-65. PubMed ID: 3037010
[TBL] [Abstract][Full Text] [Related]
35. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
36. Antigenic structure of chimeras of type 1 and type 3 poliovirus involving antigenic site 1.
Minor PD; Ferguson M; Katrak K; Wood D; John A; Howlett J; Dunn G; Burke K; Almond JW
J Gen Virol; 1990 Nov; 71 ( Pt 11)():2543-51. PubMed ID: 1701474
[TBL] [Abstract][Full Text] [Related]
37. Expression of a foreign epitope on the surface of the adenovirus hexon.
Crompton J; Toogood CI; Wallis N; Hay RT
J Gen Virol; 1994 Jan; 75 ( Pt 1)():133-9. PubMed ID: 7509367
[TBL] [Abstract][Full Text] [Related]
38. Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.
Puligedda RD; Kouiavskaia D; Adekar SP; Sharma R; Devi Kattala C; Rezapkin G; Bidzhieva B; Dessain SK; Chumakov K
Antiviral Res; 2014 Aug; 108():36-43. PubMed ID: 24824031
[TBL] [Abstract][Full Text] [Related]
39. Antigenic variation among 173 strains of type 3 poliovirus isolated in Finland during the 1984 to 1985 outbreak.
Huovilainen A; Kinnunen L; Ferguson M; Hovi T
J Gen Virol; 1988 Aug; 69 ( Pt 8)():1941-8. PubMed ID: 2841408
[TBL] [Abstract][Full Text] [Related]
40. Canyon rim residues, including antigenic determinants, modulate serotype-specific binding of polioviruses to mutants of the poliovirus receptor.
Harber J; Bernhardt G; Lu HH; Sgro JY; Wimmer E
Virology; 1995 Dec; 214(2):559-70. PubMed ID: 8553558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
